Evidence map›Paper›PMID 39670019›Full record

ArticleTranslational lung cancer research2024

Prognostic impact of targetable driver alterations in resected early-stage lung cancer.

Angelika Terbuch, Selma Konjic, Verena Schlintl, Gudrun Absenger, Philipp J Jost, Jörg Lindenmann, Paul Swatek, Nikolaus John, Teresa John, Robert Wurm and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational lung cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Angelika TerbuchDivision of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.ORCID https://orcid.org/0000-0003-2918-1370
Selma KonjicDivision of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Verena SchlintlDivision of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Gudrun AbsengerDivision of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Philipp J JostDivision of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Jörg LindenmannDivision of Thoracic Surgery, Department of Surgery, Medical University of Graz, Graz, Austria.
Paul SwatekDivision of Thoracic Surgery, Department of Surgery, Medical University of Graz, Graz, Austria.
Nikolaus JohnDivision of Pulmonology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Teresa JohnDivision of Pulmonology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Robert WurmDivision of Pulmonology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Martin ZachariasDiagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria.
Florian PoschDivision of Hematology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Maximilian J HochmairKarl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna, Austria.
Hannah FabikanKarl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna, Austria.
Christoph WeinlingerKarl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna, Austria.
Oliver IlliniKarl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna, Austria.
Lena HorvathDivision of Hematology and Oncology, Department of Internal Medicine V, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria.
Gabriele GamerithDivision of Hematology and Oncology, Department of Internal Medicine V, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria.
Dominik WolfDivision of Hematology and Oncology, Department of Internal Medicine V, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria.
Florian AugustinDepartment of Visceral, Transplant and Thoracic Surgery, Medical University of Innsbruck, Innsbruck, Austria.
Luka BrcicDiagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Apart from Methods: All consecutive patients who underwent surgery with curative intent for NSCLC (stage I-III) with targetable mutations between January 2015 and December 2020 at three Austrian institutions were identified and compared with tumors without targetable molecular alterations. Tumors with the Results: One hundred and sixty subjects had tumors with molecular alterations and 355 subjects served as control cohort. There was a higher prevalence of female sex (P<0.001) and never-smokers (P=0.01) among patients with tumors harboring oncogenic driver mutations. The three most common alterations were the Conclusions: NSCLC patients with resected tumors that harbor molecular alterations have the same recurrence risk as patients with tumors without molecular alterations if treated with surgery plus chemotherapy when indicated.

Indexed as

early-stagemolecular alterationsNon-small cell lung cancer (NSCLC)prognosis

Identifiers

PMID39670019
PMCPMC11632426

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.